Introduction

AstraZeneca PLC (LSE:AZN) is the largest constituent of the FTSE 100 by market capitalisation, with a market value of around 318.9 billion US dollars. The Cambridge-headquartered biopharmaceutical group has become a defining name in global healthcare, with an oncology franchise that ranks among the most valuable in the industry, a fast-expanding rare disease unit and a growing presence in cardiovascular, renal, metabolic and respiratory medicine.

For investors tracking the UK's blue-chip benchmark, AstraZeneca matters disproportionately. Its sheer size means a 1% move in the share price can shift the FTSE 100 by several index points on its own, and its earnings momentum often sets the tone for the European pharmaceutical sector. With the share price trading near 14,950 pence in mid-April 2026 and a trailing price-to-earnings ratio of about 30, AZN is also one of the more expensively rated names in the index, reflecting expectations of continued double-digit earnings growth.

This article looks at the business, the recent performance, the financial picture, the headline risks and the outlook investors and observers are watching.

Company overview

AstraZeneca is one of the world's largest research-based biopharmaceutical companies. The group designs, manufactures and markets prescription medicines across four core therapy areas: oncology; biopharmaceuticals (which combines cardiovascular, renal and metabolism with respiratory and immunology); rare disease; and vaccines and immune therapies. Oncology is the dominant engine, contributing the largest share of group revenue and including blockbusters such as Tagrisso for non-small cell lung cancer, Imfinzi in immuno-oncology, Lynparza in PARP inhibition, Calquence in chronic lymphocytic leukaemia and the antibody-drug conjugate Enhertu, partnered with Daiichi Sankyo.

The biopharmaceuticals business is anchored by Farxiga in diabetes and heart failure and a portfolio of respiratory medicines including Symbicort and Fasenra. The rare disease unit, built around the 2021 acquisition of Alexion, contributes Ultomiris and Soliris in complement-mediated disorders. Vaccines and immune therapies cover both legacy products and the newer long-acting antibody franchise.

Geographically, AstraZeneca is unusually diversified for a UK-listed company. The United States accounts for the largest single share of revenue, followed by Europe and a sizeable emerging-markets business in which China is a particularly important contributor. Manufacturing and research footprints span the United Kingdom, Sweden, the United States, China and several other countries, with major research hubs in Cambridge (UK), Gaithersburg (US) and Gothenburg (Sweden).

The group has built a strong position in biologics and antibody-drug conjugates, supported by significant capital investment in dedicated manufacturing capacity. Strategic collaborations and licensing arrangements remain a regular feature of the strategy, with partnerships across cell therapy, radio-conjugates and weight management adjacencies adding to the breadth of the pipeline.

Recent share price performance

AstraZeneca shares were quoted at 14,950 pence in the snapshot from mid-April 2026, slipping a modest 0.25% on the day on volume of around 127,000 shares. The trailing price-to-earnings multiple of about 30 sits comfortably above the FTSE 100 average and reflects investors' willingness to pay a premium for the group's visible pipeline and oncology growth trajectory.

Over the past two to three years, AZN's share price has been driven by a combination of strong oncology launches, accretive late-stage data readouts and steady execution on cost discipline. Periods of weakness have typically been linked to setbacks at individual trial readouts, concerns about pricing pressure in the United States and pockets of softness in the China business. The stock's relative volume of 0.06 in the latest snapshot suggests a quiet trading session rather than a meaningful repositioning by institutional investors.

The diluted earnings per share figure of 6.71 US dollars on a trailing twelve-month basis is up roughly 41% year-on-year, a striking pace of growth for a company of AstraZeneca's size and one of the key reasons the rating has held up despite broader concerns about valuations across European pharma.

Key business drivers

Oncology remains the central growth driver. Tagrisso, Imfinzi, Lynparza, Calquence and Enhertu collectively contribute the majority of incremental sales, supported by a steady drumbeat of label extensions and earlier-line approvals. Each new indication can meaningfully expand the addressable patient population, which in oncology often translates directly into multi-hundred-million-dollar annual revenue lifts.

Beyond oncology, the cardiovascular, renal and metabolism franchise has benefited from the broadening role of SGLT2 inhibitors in heart failure and chronic kidney disease, while the rare disease portfolio acquired with Alexion has provided durable, premium-priced revenue streams.

Two structural factors influence the entire business. The first is research and development productivity: AstraZeneca's late-stage pipeline is among the largest in the industry and the cadence of high-quality data readouts has been a major source of share-price support. The second is patent protection. The group has limited near-term loss-of-exclusivity exposure compared with several large peers, which insulates revenue better than at companies facing imminent biosimilar or generic competition.

Currency is also relevant. Although AstraZeneca reports in US dollars, it is listed in London and pays a dollar-denominated dividend, so sterling investors are exposed to GBP/USD movements both at the operating level and at the dividend level.

A further driver is operating leverage. As the oncology and rare disease franchises have scaled, more revenue dollars have flowed through to operating profit. Continued growth in higher-margin specialty medicines, combined with disciplined commercial spend, helps support the medium-term ambition for further core operating margin expansion. Manufacturing complexity for biologics and antibody-drug conjugates is also a competitive moat that protects against rapid biosimilar entry once exclusivity expires.

Financial overview

AstraZeneca's reported revenue base has scaled into the high tens of billions of dollars on an annual basis, with double-digit total revenue growth supported by oncology and rare disease. Core operating margins have improved as the integration of Alexion has matured and as scale efficiencies have flowed through, with management consistently signalling further margin expansion as part of its medium-term framework.

Trailing twelve-month diluted earnings per share of 6.71 US dollars, up around 41% year-on-year, illustrates the operational leverage embedded in the business. Free cash flow has comfortably supported the dividend, ongoing investment in research and development at over 20% of sales, and a measured deleveraging of the balance sheet following the Alexion deal.

Net debt has been steadily reduced from peak levels, helped by strong cash generation and disciplined capital allocation. The dividend, paid twice yearly in US dollars, has been raised in recent years after a long period of being held flat, reflecting management's increased confidence in the cash-flow profile.

Recent news and announcements

Recent newsflow around AstraZeneca has been dominated by clinical readouts across the oncology pipeline, particularly in lung, breast and gastrointestinal cancers. Label expansions for Enhertu and Tagrisso, updates on next-generation antibody-drug conjugates and progress on cell therapies have featured prominently at major medical congresses.

On the strategic front, management has continued to emphasise its long-range ambition to grow group revenue substantially by the end of the decade, supported by more than a dozen potential blockbuster launches. Bolt-on acquisitions and licensing deals have remained part of the toolkit, with a particular focus on expanding capabilities in radio-conjugates, cell therapy and weight management adjacencies.

Geopolitically, the China business has remained an area of particular focus given the importance of that market. Investors have also paid close attention to commentary on US drug pricing, given ongoing implementation of provisions affecting Medicare price negotiation.

Investor day messaging has reinforced the longer-term ambition to grow group revenue significantly by 2030, supported by oncology cell therapies, the next generation of antibody-drug conjugates, weight-management adjacencies and continued expansion of the rare disease franchise. Shareholders have also focused on capital allocation discipline, manufacturing capacity expansion and the cadence of dividend increases following several years of essentially flat distributions.

Risks and challenges

AstraZeneca faces the risks common to large pharmaceutical companies. Pipeline failures or disappointing trial readouts can wipe billions off the market capitalisation in a single session. Regulatory delays, label restrictions or safety findings can constrain the commercial potential of even successful molecules.

Pricing and reimbursement pressure is intensifying in the United States, where price negotiation for selected high-spend drugs is being implemented under federal legislation, and in Europe, where payers continue to push back on launch prices. Although AstraZeneca's near-term loss-of-exclusivity exposure is modest, several products will face biosimilar or generic competition over the medium term and the group will need pipeline launches to more than offset that erosion.

Operational risks include manufacturing complexity, particularly for biologics and antibody-drug conjugates, and the need to scale supply for fast-growing launch products. Macroeconomic and currency risks are also relevant given the geographic spread of revenue. Finally, the China business is exposed to local pricing dynamics, anti-corruption enforcement and the broader US-China relationship.

Reputational and litigation risks should not be underestimated either. Pharmaceutical companies face product liability claims, ongoing scrutiny over marketing practices and increasing transparency requirements. Cybersecurity is an additional concern given the volume of clinical trial data and intellectual property held across the organisation. Each of these factors is manageable in isolation but can become material if combined with adverse market conditions.

Outlook

The medium-term outlook for AstraZeneca rests largely on its pipeline. Management has set out an ambition to deliver significant revenue growth by 2030, supported by a slate of late-stage assets in oncology, rare disease and cardiovascular, renal and metabolic disease. If a meaningful share of these candidates reach market, revenue and earnings could continue to compound at attractive rates and the group's valuation premium may be defensible.

Equally, the bar set by the current rating is high. Investors are effectively paying for successful execution on multiple fronts, and shortfalls on flagship readouts could compress the multiple even if absolute earnings continue to grow. Capital allocation will remain a focus, with the market watching how aggressively the company pursues bolt-on acquisitions and how it balances reinvestment with shareholder returns.

From a sector perspective, AstraZeneca is well placed to benefit from demographic trends, the continued shift towards precision medicine and the growing role of biologics and antibody-drug conjugates in cancer care. Headwinds from US pricing reform and geopolitical tension with China are real but, on current trajectories, manageable within a broader growth narrative.

Conclusion

AstraZeneca is the heavyweight of the FTSE 100 and a bellwether for European pharmaceuticals. Its scale, pipeline depth and oncology leadership have driven a striking re-rating over recent years, and trailing earnings growth of more than 40% supports the elevated valuation multiple. At the same time, a price-to-earnings ratio of around 30 leaves limited margin for execution disappointment, and investors are increasingly focused on the cadence of pipeline delivery against management's longer-term revenue ambitions.

Whether viewed as the dominant UK-listed pharmaceutical company, a global oncology leader or simply the largest weight in the FTSE 100, AstraZeneca's performance will continue to influence the index well beyond its immediate sector. For anyone monitoring the FTSE 100, AZN remains an essential name to follow.